Presentations
Grothey A., Hoefman S., Ruppert M., Vis P., Zisowsky J., Cutsem E., Dochy E.v. Fiala-buskies S., Cleton A., Ploeger B. Exploration of efficacious alternative regorafenib regimens to manage hand − foot skin reaction. ESMO, 2019.
Ploeger B., Hoefman S., Ruppert M., Vis P., Zisowsky J., Grothey A., Cutsem E., Dochy E.v., Cleton A. Exploration of alternative regorafenib regimens to manage hand – foot skin reaction. European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer, 2019. [Link to publication]
Berkhout J., Post T.M., Xu L., Zhang L., Wendland J., Faessel H., Vakilynejad M. Application of population PK/PD modeling and simulation to inform the design of a dose-finding study in patients with schizophrenia. PAGE, 2019. [Link to publication]
Dejongh J. Ahsman M.& Snelder N. A mechanism-based population K-PD model for long-term testosterone inhibition in prostate cancer patients under intermittent androgen deprivation therapy. PAGE 2019/ IATDMCTS 2019. [Link to publication]
Bosch R., Petrone M.,Hoefman S., Arends R., Vicini P., Snelder N. Integrate QSP model of in vivo human glucose regulation to support development of a glucagon/GLP-1 dual agonist. WCDT 2019. [Link to publication]
Bosch R., Petrone M., Hoefman S., Arends R., Vicini P., Snelder N. Predicting the effect of GLP-1 agonists on glucose and HbA1c with a 4GI-HbA1c model. ACOP, 2019. [Link to publication]
Berg P.v.d., Post T.M., Gao W., Miller R., Kesisoglou F., Arrington L., Rizk M.L. Application of a MK-3682 minimal PBPK-PD model to explain discrepancy between enhanced efficacy and PK in the presence of itraconazole. ACoP9, 2018.
Hooijmaijers R., Fidler M., Schoemaker R., Trame M.N., Wang W., Wilkins J., Post T.M. ShinyMixR : A project-centric R / Shiny run management tool for nlmixr. PAGE, 2018. [Link to publication]
Berg P.v.d., Post T.M., Gao W., Miller R., Kesisoglou F., Arrington L., Rizk M.L. An HCV nucleoside inhibitor MK-3682 minimal PBPK-PD model for application in hypothesis generation regarding metabolic pathways and perturbations under various conditions. PAGE, 2018. [Link to publication]
Bosch R., Petrone M., Vicini P., Snelder N. A novel integrated QSP model of in vivo human glucose regulation to support development of a glucagon/GLP-1 dual agonist. PAGE, 2018. [Link to publication]